SUMMARY -Postherpetic neuralgia (PHN) characterized by chronic neuropathic pain is a common complication of herpes zoster. We investigated the effi cacy, safety and cost of treating refractory chronic neuropathic pain with 5% topical lidocaine plaster (TLP) in a female patient attending pain unit at a small county hospital. An 80-year-old female diagnosed with PHN presented with severe left intercostal allodynia and hyperalgesia up to the root of the fourth to tenth thoracic dermatome. We administered the well established fi rst-and second-line specifi c medications for PHN, but treatment regimens were not effi cient. Th en we introduced TLP and analyzed data from initial assessment and throughout follow up of 1313 days. Th e effi cacy of treatment was based on pain severity that was assessed using the Short-Form McGill Pain Questionnaire and the related visual analog scale. In the last two years of observation, signifi cant reduction was recorded in healthcare resource utilization (changes correlated with substantial reduction in direct cost (2012-2013: -425.90 €; and 2013-2014: -1,435 €) and clinically relevant reduction in pain severity. No unusual side eff ects were observed. In conclusion, treatment of PHN with 5% lidocaine plaster demonstrated effi cacy in reducing pain severity and cost of medical care with a satisfactory safety profi le. A starting point for future studies should be comparison of diff erent treatment protocols and upgrading the knowledge, especially related to the cost of PHN treatment.
Introduction
Herpes zoster is caused by reactivation of the varicella zoster virus in cranial nerves and spinal root ganglia 1, 2 . In some patients, pain does not resolve when the rash heals but continues for weeks, months or years; this persistent, neuropathic pain is termed postherpetic neuralgia (PHN) 3, 4 . Th e incidence is low among individuals younger than 40, ranging from 0.9 to 1.9 cases per 1000 patient-years, and increases with age to 9.4 cases per 1000 patient-years among individuals aged ≥80 [5] [6] [7] . Anatomic PHN distribution follows the pattern of dermatomes aff ected by herpes zoster. Pain is characterized by burning, tingling or stinging, and is of a varying intensity sometimes described as unbearable. Hyperalgesia, hyperesthesia or allodynia may be associated 7 . Th e management of PHN is expensive, and patients often continue to suff er severe pain despite taking prescribed analgesics 8 . Recent systematic reviews of treatment options have concluded that tricyclic antidepressants are the most effi cacious option; however, when patients become intolerant to prescribed medications and the potential for side eff ects is included in decision making, the administration of 5% topical lidocaine plaster (TLP) is useful because of its localized effi cacy and low incidence of systemic adverse reactions 9, 10 . Th is case report describes clinical presentation of PHN developed in an 80-year-old female patient with localized refractory neuropathic pain predominated by allodynia, for which TLP represented an alternative with benefi ts outweighing the risks. We analyzed the type of neuropathic pain observed and evaluated duration, effi cacy and safety of treatment, costs and concomitant administration of co-analgesic and other antineuropathic drugs that may interfere with comorbidity.
Case Report
Th e 8 0-year-old female patient with small bullous lesions on the left sole of the foot was seen by a dermatologist, who made the diagnosis of herpes zoster in the healing phase of the lesions, and prescribed antibiotics and nonsteroidal anti-infl ammatory drugs (NSAIDs). Treatment protocol was carried out according to recommendations issued by the Advisory Committee on Immunization Practices (ACIP). Pain severity was assessed using the Short-Form McGill Pain Questionnaire (SF-MPQ) and the related visual analog scale (VAS). Approval for its use was obtained from the authors (Immpact Group, Montreal, Canada). Medications were preceded by standardized instructions to patients, and each patient visit was performed in a quiet room with no distractions. Th e course of treatment, medications, side eff ects, VAS and costs are shown in Table 1 .
Th e treatment was administered from November 2, 2010 to March 11, 2014 (1313 days). Key points of the treatment protocol were as follows: initial outpatient examination was performed at 6 weeks, on November 2, 2010. After withdrawal of cutaneous effl orescences, the patient was referred to the Pain Control Unit, Dr Ivo Pedišić County Hospital in Sisak, Croatia. Th e pain was spreading throughout the left thoracic region with recurrent painful attacks. Th e patient reported strong burning sensation, tingling and painful touch. On physical evaluation, she presented pain provoked by typically nonpainful stimuli (allodynia) and hyperalgesia in the left thoracic region from the root of the fourth thoracic dermatome to the tenth thoracic dermatome. Th e treatment started with gabapentin (fi rst week, 75 mg/day; second week, 150 mg/day; and third week, 300 mg/day). Simultaneously, oral tricyclic antidepressants (TCAs) were introduced at a dosage of 25 mg/day, along with long-acting form of tramadol in a dosage of 100 mg/day and 5% TLP. VAS was 8 and Present Pain Intensity (PPI) was 4.
On September 5, 2011, i.e. 337 days of treatment initiation, amitriptyline at a dose of 10 mg/day in the evening and long-acting tramadol at the average daily dose of 300 mg/day were added. VAS was 5-8, with daily fl uctuations, and PPI was 2-4. On June 24, 2011, 264 days of treatment introduction, gabapentin and amitriptyline were administered in the same average daily doses, while tramadol was reduced to 100 mg/ day. VAS was 5-8 and PPI was 2-4. On October 13, 2011, 413 days of treatment initiation, the average daily dose of gabapentin was reduced to 800 mg/day. A combination of tramadol (100 mg/day) and paracetamol (900 mg/day) was introduced, resulting in reduced pain severity. VAS was 5-8 and PPI was 2-4. On April 5, 2012, 640 days of treatment initiation, amitriptyline was discontinued and carbamazepine introduced (800 mg/day). Tramadol was introduced in the form of drops (200 mg/day, three times per week). Th e level of allodynia was reduced. Insomnia was not associated with pain intensity. On August 20, 2012, injections of diluted levobupivacaine with dexamethasone were administered in the paravertebral area from the 4 th to 10 th thoracic dermatome. Th erapeutic eff ect was complemented with transcutaneous electrical nerve stimulation (TENS, 220 Hz, 110 μs). VAS was 5-8 and PPI was 2-4. On December 1, 2013, 776 days of treatment introduction, opioid analgesic was discontinued due to side eff ects (diplopia, pruritus, alopecia, dry mouth and dizziness]. Carbamazepine (100 mg/day) and TLP were administered continuously. On November 10, 2013, 1181 days of initial examination, oral non-steroidal drug was introduced (400 mg/day). Mild burning sensation was present in the lower chest area at the 6 th to 9 th dermatome. During 2013, TLP was administered every 12 hours three days a week. VAS was 6 and PPI was 0. Final follow up examination was performed on March 11, 2014, 1313 days of the fi rst examination. During the period from previous follow up examination, the patient had received one course of lidocaine with methylprednisolone (paravertebral block). All medications were discontinued. During the last two years of treatment, substantial reductions in direct costs (2012-2013: -470.90 €; and 2013-2014: -1,417 €) were recorded, without adverse eff ects.
Discussion
Th e effi cacy of a combination of medications should be considered to achieve additional or even synergistic eff ects in the treatment of PHN 10 , as shown in this case report. Th e results recorded in the case presented demonstrate the effi cacy and safety profi le with very few local adverse reactions, as well as simplifi ed treatment protocol and reduction in outpatient treatment costs and concomitant medication.
We present our results with the use of original treatment protocol for PHN. Th e main idea for creating a protocol for the treatment of PHN is the fact that topical analgesics have lowest price among medicaments intended for PHN therapy, and that medical resources at a small county hospital are strictly limited, with a tendency to further reduction. Several limitations associated with this case report should be considered when interpreting the results. First, these results are based on a deterministic cost-eff ectiveness model and the fi nal model must be a fully probabilistic model. Second, not included in this study, is the extensive sensitivity analysis around the base case deterministic cost-eff ectiveness estimates to fully explore the impact of uncertainty on our results. And fi nally, there is concern about comparability of the presented costs after switching to pregaba- Th e results presented could be especially interesting for the treatment of PHN in small or/and middleincome countries where medical resources are strictly limited, with a tendency to further reduction. Future complementary prospective studies should be undertaken to demonstrate the favorable benefi t-risk ratio in specifi c populations and to improve the body of knowledge on the use of TLP for PHN.
